During these studies, we reported that–RK-33, specifically targets DDX3 and abrogates its function in cells with elevated DDX3 expression levels and, as such, has a potential to be a drug that can target a subset of CRC patients [45]. The gene discussed is DDX3X; the disease is colorectal carcinoma.